Skip to main content

Closed

RCUS: Arcus Biosciences, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+120.5% / yr

Operating margin-168.6%

ROIC-49.7%

Financially safe

Stretched

Debt / equity0.22×

Interest coverage-18.1×

Current ratio4.04×

Arcus Biosciences, Inc.

RCUSNew York Stock Exchange·USD·Closed

Arcus Biosciences, Inc.

RCUSNew York Stock Exchange·USD·Closed

$28.19

−0.21%

$28.19

−$0.06 (0.21%)

52W Range

85thpctl

Volume

0.82×avg

Mkt Cap

3.55BUSD

P/E

-8.9TTM

Div Yield

–ann

52W Range

85thpctl

Volume

0.82×avg

Market Cap

3.55BUSD

P/E Ratio

-8.9TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings